|
|
|
|
LEADER |
03618nma a2200985 u 4500 |
001 |
EB002048806 |
003 |
EBX01000000000000001192472 |
005 |
00000000000000.0 |
007 |
cr||||||||||||||||||||| |
008 |
220822 ||| eng |
020 |
|
|
|a 9783036528595
|
020 |
|
|
|a 9783036528588
|
020 |
|
|
|a books978-3-0365-2858-8
|
100 |
1 |
|
|a Sumiyoshi, Tomiki
|
245 |
0 |
0 |
|a Psychoneurobiology Research and Personalized Treatment of Schizophrenia
|h Elektronische Ressource
|
260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2022
|
300 |
|
|
|a 1 electronic resource (133 p.)
|
653 |
|
|
|a superior temporal sulcus
|
653 |
|
|
|a microglia
|
653 |
|
|
|a test battery
|
653 |
|
|
|a systematic review
|
653 |
|
|
|a needs survey
|
653 |
|
|
|a metabolic syndrome
|
653 |
|
|
|a event-related potentials
|
653 |
|
|
|a CX3CR1
|
653 |
|
|
|a optogenetics
|
653 |
|
|
|a neuromodulation
|
653 |
|
|
|a cognition
|
653 |
|
|
|a genes
|
653 |
|
|
|a medication
|
653 |
|
|
|a gyrification
|
653 |
|
|
|a pharmacogenetics
|
653 |
|
|
|a n/a
|
653 |
|
|
|a weight gain
|
653 |
|
|
|a social cognition
|
653 |
|
|
|a diagnosis
|
653 |
|
|
|a olfactory neuroepithelium
|
653 |
|
|
|a first-episode psychosis
|
653 |
|
|
|a developmental disorders
|
653 |
|
|
|a superior temporal gyrus
|
653 |
|
|
|a cannabis
|
653 |
|
|
|a body mass index
|
653 |
|
|
|a schizotypal disorder
|
653 |
|
|
|a complement
|
653 |
|
|
|a metacognitive training
|
653 |
|
|
|a MTREX
|
653 |
|
|
|a experiment
|
653 |
|
|
|a social functioning
|
653 |
|
|
|a at risk mental state
|
653 |
|
|
|a transcranial direct current stimulation (tDCS)
|
653 |
|
|
|a ZNF326
|
653 |
|
|
|a magnetic resonance imaging
|
653 |
|
|
|a social function
|
653 |
|
|
|a schizophrenia
|
653 |
|
|
|a sessions
|
653 |
|
|
|a latency
|
653 |
|
|
|a medial prefrontal cortex
|
653 |
|
|
|a synaptic pruning
|
653 |
|
|
|a facial expression recognition
|
653 |
|
|
|a P300
|
653 |
|
|
|a quality of life
|
653 |
|
|
|a proteomics
|
653 |
|
|
|a piccolo
|
653 |
|
|
|a dorsal striatum
|
653 |
|
|
|a mental disorders
|
653 |
|
|
|a antipsychotics
|
653 |
|
|
|a neurodevelopment
|
653 |
|
|
|a RNA
|
653 |
|
|
|a psychosis
|
653 |
|
|
|a metabolism
|
653 |
|
|
|a serotonin
|
653 |
|
|
|a cognitive insight
|
653 |
|
|
|a clinical high-risk
|
653 |
|
|
|a Medicine and Nursing / bicssc
|
653 |
|
|
|a presynaptic cytomatrix protein
|
700 |
1 |
|
|a Sumiyoshi, Tomiki
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
028 |
5 |
0 |
|a 10.3390/books978-3-0365-2858-8
|
856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/4865
|7 0
|x Verlag
|3 Volltext
|
856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/78772
|z DOAB: description of the publication
|
082 |
0 |
|
|a 610
|
082 |
0 |
|
|a 333
|
520 |
|
|
|a Schizophrenia is a common disease characterized by psychotic symptoms (e.g., delusion, hallucinations, blunted affect) and disturbances of cognitive function (e.g., memory, abstraction, attention). If not treated properly, patients may experience serious consequences in terms of social function. Much endeavor in several disciplines of medical science has been made to overcome the paucity of effective treatments for unmet needs, including cognitive impairment associated with schizophrenia.This Book, contributed by experts from various regions of the globe, provides up-to-date information to facilitate the development of personal therapeutics for this enigmatic illness.
|